Advertisement

Omega-3 Fatty Acid and Cardiovascular Outcomes: Insights From Recent Clinical Trials

  • Xiaoming Jia
  • Payal Kohli
  • Salim S. ViraniEmail author
Coronary Heart Disease (S. Virani and S. Naderi, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Coronary Heart Disease

Abstract

Purpose of Review

Omega-3 fatty acids (ω-3 FA) are among the most well-recognized health supplements but their cardiovascular benefits have long been controversial owing to inconsistent results from previous cardiovascular outcomes trials (CVOT). In this article, we provide a short review of existing literature followed by recent randomized clinical trial data, with a discussion of the potential clinical implications of these new findings.

Recent Findings

Data from the randomized, controlled trial REDUCE-IT, when viewed within the context of other recently published trials ASCEND and VITAL, add to a growing body of evidence on the use of ω-3 FA therapies in the treatment of atherosclerotic cardiovascular disease (ASCVD).

Summary

Given the different formulations, dosages, and patient populations studied, CVOTs of ω-3 FA have provided valuable insight into the use of these agents in cardioprotection. Current data suggest that higher dosages of pure eicosapentaenoic acid ω-3 FA formulations provide additional benefit in reduction of ASCVD events.

Keywords

Omega-3 fatty acid Eicosapentaenoic acid Docosahexaenoic acid Icosapent ethyl Cardiovascular outcomes Lipids 

Notes

Compliance with Ethical Standards

Conflict of Interest

Xiaoming Jia, Payal Kohli, Salim S. Virani declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Gawrisch K, Soubias O. Structure and dynamics of polyunsaturated hydrocarbon chains in lipid bilayers—significance for GPCR function. Chem Phys Lipids. 2008;153(1):64–75.CrossRefGoogle Scholar
  2. 2.
    Li GR, Sun HY, Zhang XH, Cheng LC, Chiu SW, Tse HF, et al. Omega-3 polyunsaturated fatty acids inhibit transient outward and ultra-rapid delayed rectifier K+ currents and Na+ current in human atrial myocytes. Cardiovasc Res. 2009;81(2):286–93.CrossRefGoogle Scholar
  3. 3.
    Lee JY, Plakidas A, Lee WH, Heikkinen A, Chanmugam P, Bray G, et al. Differential modulation of toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J Lipid Res. 2003;44(3):479–86.CrossRefGoogle Scholar
  4. 4.
    Schroeder F, Petrescu AD, Huang H, Atshaves BP, McIntosh AL, Martin GG, et al. Role of fatty acid binding proteins and long chain fatty acids in modulating nuclear receptors and gene transcription. Lipids. 2008;43(1):1–17.CrossRefGoogle Scholar
  5. 5.
    Mozaffarian D, Lemaitre RN, Kuller LH, Burke GL, Tracy RP, Siscovick DS, et al. Cardiac benefits of fish consumption may depend on the type of fish meal consumed: the cardiovascular health study. Circulation. 2003;107(10):1372–7.CrossRefGoogle Scholar
  6. 6.
    König A, Bouzan C, Cohen JT, Connor WE, Kris-Etherton PM, Gray GM, et al. A quantitative analysis of fish consumption and coronary heart disease mortality. Am J Prev Med. 2005;29(4):335–46.CrossRefGoogle Scholar
  7. 7.
    Bouzan C, Cohen JT, Connor WE, Kris-Etherton PM, Gray GM, König A, et al. A quantitative analysis of fish consumption and stroke risk. Am J Prev Med. 2005;29(4):347–52.CrossRefGoogle Scholar
  8. 8.
    Brenna JT, Salem N, Sinclair AJ, Cunnane SC. International Society for the Study of fatty acids and Lipids ISSF. Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot Essent Fat Acids. 2009;80(2–3):85–91.CrossRefGoogle Scholar
  9. 9.
    Abedi E, Sahari MA. Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr. 2014;2(5):443–63.CrossRefGoogle Scholar
  10. 10.
    US Food & Drug Administration. Approval package for application number 21–654. 2004.Google Scholar
  11. 11.
    US Food & Drug Administration. Approval package for: application number 202057Orig1s000. 2012.Google Scholar
  12. 12.
    Do R, Willer CJ, Schmidt EM, Sengupta S, Gao C, Peloso GM, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345–52.CrossRefGoogle Scholar
  13. 13.
    Musunuru K, Kathiresan S. Surprises from genetic analyses of lipid risk factors for atherosclerosis. Circ Res. 2016;118(4):579–85.CrossRefGoogle Scholar
  14. 14.
    Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330–43.CrossRefGoogle Scholar
  15. 15.
    Mozaffarian D, Wu JH. Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol. 2011;58(20):2047–67.CrossRefGoogle Scholar
  16. 16.
    •• Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. N Engl J Med. 2018;379(16):1540–50. Large CVOT of ω-3 FA in primary prevention of ASCVD in patients with diabetes showing no significance in reduction of primary endpoint in the active treatment arm compared with placebo. CrossRefGoogle Scholar
  17. 17.
    •• Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. N Engl J Med. 2019;380(1):23–32. Large CVOT of ω-3 FA with and without vitamin D in primary prevention of ASCVD no significance in reduction of primary endpoint in the active treatment arm compared with placebo. Google Scholar
  18. 18.
    •• Bhatt DL, Steg G, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11–22. CVOT of highly pure EPA ethyl ester, icosapent ethyl, showing reduction in primary efficacy endpoint compared with placebo. Google Scholar
  19. 19.
    GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354(9177):447–55.Google Scholar
  20. 20.
    Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9645):1223–30.CrossRefGoogle Scholar
  21. 21.
    Handelsman Y, Shapiro MD. Triglycerides, atherosclerosis, and cardiovascular outcome studies: focus on omega-3 fatty acids. Endocr Pract. 2017;23(1):100–12.CrossRefGoogle Scholar
  22. 22.
    Rauch B, Schiele R, Schneider S, Diller F, Victor N, Gohlke H, et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation. 2010;122(21):2152–9.CrossRefGoogle Scholar
  23. 23.
    Kromhout D, Giltay EJ, Geleijnse JM, Group AOT. N-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med. 2010;363(21):2015–26.CrossRefGoogle Scholar
  24. 24.
    Galan P, Kesse-Guyot E, Czernichow S, Briancon S, Blacher J, Hercberg S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ. 2010;341:c6273.CrossRefGoogle Scholar
  25. 25.
    Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al. N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367(4):309–18.CrossRefGoogle Scholar
  26. 26.
    Roncaglioni MC, Tombesi M, Avanzini F, Barlera S, Caimi V, Longoni P, et al. N-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368(19):1800–8.CrossRefGoogle Scholar
  27. 27.
    Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090–8.CrossRefGoogle Scholar
  28. 28.
    Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, et al. Associations of Omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals. JAMA Cardiol. 2018;3(3):225–34.CrossRefGoogle Scholar
  29. 29.
    Mason RP, Jacob RF, Shrivastava S, Sherratt SCR, Chattopadhyay A. Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes. Biochim Biophys Acta. 2016;1858(12):3131–40.CrossRefGoogle Scholar
  30. 30.
    Chang CH, Tseng PT, Chen NY, Lin PC, Lin PY, Chang JP, et al. Safety and tolerability of prescription omega-3 fatty acids: a systematic review and meta-analysis of randomized controlled trials. Prostaglandins Leukot Essent Fatty Acids. 2018;129:1–12.CrossRefGoogle Scholar
  31. 31.
    Swann PG, Venton DL, Le Breton GC. Eicosapentaenoic acid and docosahexaenoic acid are antagonists at the thromboxane A2/prostaglandin H2 receptor in human platelets. FEBS Lett. 1989;243(2):244–6.CrossRefGoogle Scholar
  32. 32.
    Bays HE, Ballantyne CM, Doyle RT, Juliano RA, Philip S. Icosapent ethyl: Eicosapentaenoic acid concentration and triglyceride-lowering effects across clinical studies. Prostaglandins Other Lipid Mediat. 2016;125:57–64.CrossRefGoogle Scholar
  33. 33.
    Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22.CrossRefGoogle Scholar
  34. 34.
    Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–107.CrossRefGoogle Scholar
  35. 35.
    Baum SJ. ANCHOR trial conclusions regarding the effects of pure eicosapentaenoic acid on low-density lipoprotein cholesterol. Am J Cardiol. 2013;111(3):454–5.CrossRefGoogle Scholar
  36. 36.
    • Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol. 2018;41(10):1281–8. Ongoing CVOT of ω-3 FA assessing efficacy of 4g/day of EPA+DHA mixture in reduction of ASCVD events. CrossRefGoogle Scholar
  37. 37.
    Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007;298(3):299–308.CrossRefGoogle Scholar
  38. 38.
    Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, et al. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA lipid intervention study (JELIS). Atherosclerosis. 2008;200(1):135–40.CrossRefGoogle Scholar
  39. 39.
    Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105–15.CrossRefGoogle Scholar
  40. 40.
    Mullen A, Loscher CE, Roche HM. Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages. J Nutr Biochem. 2010;21(5):444–50.CrossRefGoogle Scholar
  41. 41.
    Krämer HJ, Stevens J, Grimminger F, Seeger W. Fish oil fatty acids and human platelets: dose-dependent decrease in dienoic and increase in trienoic thromboxane generation. Biochem Pharmacol. 1996;52(8):1211–7.CrossRefGoogle Scholar
  42. 42.
    Leifert WR, McMurchie EJ, Saint DA. Inhibition of cardiac sodium currents in adult rat myocytes by n-3 polyunsaturated fatty acids. J Physiol. 1999;520(Pt 3):671–9.CrossRefGoogle Scholar
  43. 43.
    Xiao YF, Ke Q, Chen Y, Morgan JP, Leaf A. Inhibitory effect of n-3 fish oil fatty acids on cardiac Na+/Ca2+ exchange currents in HEK293t cells. Biochem Biophys Res Commun. 2004;321(1):116–23.CrossRefGoogle Scholar
  44. 44.
    London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and office of dietary supplements Omega-3 fatty acids and their role in cardiac Arrhythmogenesis workshop. Circulation. 2007;116(10):e320–35.CrossRefGoogle Scholar
  45. 45.
    Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304(21):2363–72.CrossRefGoogle Scholar
  46. 46.
    Frost L, Vestergaard P. N-3 fatty acids consumed from fish and risk of atrial fibrillation or flutter: the Danish diet, Cancer, and health study. Am J Clin Nutr. 2005;81(1):50–4.CrossRefGoogle Scholar
  47. 47.
    Jia X, Miedema M, Virani SS, Kohli P. Not all fish oils are created equal: insight from REDUCE-IT. 2018. https://www.acc.org/latest-in-cardiology/articles/2018/11/14/13/59/not-all-fish-oils-are-created-equal. Accessed on 30 Nov 2018.

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2019

Authors and Affiliations

  1. 1.Section of Cardiovascular Research, Department of MedicineBaylor College of MedicineHoustonUSA
  2. 2.Heart and Vascular Institute of ColoradoSCL HealthDenverUSA
  3. 3.Health Policy, Quality and Informatics ProgramMichael E. DeBakey Veterans Affairs Medical Center Health Services Research and Development Center for InnovationsHoustonUSA
  4. 4.Health Services Research and DevelopmentMichael E. DeBakey Veterans Affairs Medical CenterHoustonUSA

Personalised recommendations